Overview
In Argentina, peptides intended for human use are treated as medicines and fall under national medicines law, which requires prior government authorization for their import, manufacture and sale. Peptide drugs that ANMAT has registered (such as semaglutide products) are legally available but only as prescription medicines dispensed through licensed pharmacies, while peptides with no ANMAT registration — including research-grade compounds sold online or through social media — cannot lawfully be marketed and have repeatedly been banned by ANMAT disposition. Personal importation of unregistered medicines is possible only through a special ANMAT-administered regime that requires a doctor's prescription and case-by-case approval. There is no Argentine equivalent of a 'research chemical' or compounding-pharmacy carve-out for peptides such as BPC-157 or TB-500.
Key Points
- Argentina's Medicines Law No. 16.463 subjects the import, export, production, fractionation, marketing and storage of drugs, chemical products and any other product used in human medicine to prior authorization and official control, and those activities may only be carried out in authorized establishments under a qualified technical director. [1]
- Peptide medicines reach the legal market only by inscription in ANMAT's Registry of Medicinal Specialties (REM); for example, ANMAT authorized the registration of the semaglutide product WEGOVY by Disposition No. 5591/2023. [2]
- ANMAT has confirmed that the tirzepatide-containing medicines legally registered in Argentina are sold only under medical prescription, and by Disposition 2369/26 it prohibited the use, sale and distribution of the unregistered product 'Lipoless 2,5 mg / Tirzepatida' that was being sold through online platforms. [3]
- ANMAT prohibited the nationwide sale and distribution of 'TIRZEC 5' (tirzepatide) by Disposition No. 8203/25 because it was a product without health registration or authorization in the country and of unknown origin, composition and manufacturing conditions. [4]
- By Disposition 5842/25, ANMAT banned the use, marketing and distribution throughout the national territory of any dose, presentation or batch identified as 'Ozempíc Semaglutida Tablets USP'. [5]
- Personal importation of medicines not registered in Argentina runs through the RAEM-NR regime, in which ANMAT approves or rejects each request, the medicine must be prescribed by a qualified physician whose CV is submitted, the original signed prescription covers up to 60 days of treatment, and the Ezeiza customs office receives and delivers the shipment to the patient. [6]
- Following ANMAT's 2026 bans on falsified and unauthorized injectable weight-loss products offered on websites and social media, health authorities reiterated that semaglutide- and tirzepatide-containing medicines must be used only under strict medical supervision and purchased exclusively at licensed pharmacies. [7]
- No ANMAT registration, scheduling entry, or peptide-specific Argentine regulation naming BPC-157 or TB-500 was located in these searches; the conclusion that such compounds are unlawful to sell or import for human use is an inference from the general Law 16.463 registration requirement and ANMAT's enforcement pattern against unregistered injectables, not from a direct source naming those peptides. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)